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Summary
There is genetic predisposition associated with x10%
of all cancer of the prostate (CaP). By means of a ge-
nomewide search on a selection of 47 French and
German families, parametric and nonparametric linkage
(NPL) analysis allowed identification of a locus, on chro-
mosome 1q42.2-43, carrying a putative predisposing
gene for CaP (PCaP). The primary localization was con-
firmed with several markers, by use of three different
genetic models. We obtained a maximum two-point
LOD score of 2.7 with marker D1S2785. Multipoint
parametric and NPL analysis yielded maximum HLOD
and NPL scores of 2.2 and 3.1, respectively, with an
associated P value of .001. Homogeneity analysis with
multipoint LOD scores gave an estimate of the propor-
tion of families with linkage to this locus of 50%, with
a likelihood ratio of 157/1 in favor of heterogeneity.
Furthermore, the 9/47 families with early-onset CaP at
age !60 years gave multipoint LOD and NPL scores of
3.31 and 3.32, respectively, with P  .001.
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Introduction
Since the first description, in 1956 (Morganti et al.
1956), of familial aggregation of prostate cancer (CaP)
cases, several reports (Woolf 1960; Skolnick et al. 1979;
Cannon et al. 1982; Meikle et al. 1985; Spitz et al. 1991)
have confirmed that ∼10% of all CaPs are hereditary,
with an autosomal dominant inheritance (Carter et al.
1992; Gro¨nberg et al. 1997a). Recent investigations by
linkage analysis have proposed one susceptibility locus
for CaP on chromosome 1q24-25 (Smith et al. 1996).
This locus, called “HPC1” by the investigators, is still
a matter of controversy. It has been confirmed both by
two other groups (Cooney et al. 1997; Hsieh et al. 1997)
and through reanalysis and extension of the original
study (Gro¨nberg et al. 1997b). Conversely, HPC1 has
remained unconfirmed by other investigations, including
those by a U.K./Canada/Texas consortium (Eeles et al.
1997) and three North American groups (Cannon-Al-
bright and Neuhausen 1997; McIndoe et al. 1997; Thi-
bodeau et al. 1997).
To identify the genes predisposing for CaP (PCaP
genes), we have initiated an independent linkage study,
using a set of European families (French and German)
with three or more CaP patients per family (Valeri et al.
1996). In the present study we demonstrate a localiza-
tion for a PCaP gene, on chromosome 1q42.2-43, sig-
nificantly distant from the proposed locus on 1q24-25
(Smith et al. 1996).
Families and Methods
Family Collection
A family study of CaP has been undertaken since
1995, first identifying and collecting families in France
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Table 1
Characteristics of Genotyped CaP Families
Category Result
No. of families analyzed 47
Total no. of individuals genotyped 194
Total no. of affecteds genotyped 122
Average no. of CaP cases/family (range) 3.31 (3–8)
Average no. of genotyped CaP cases/family (range) 2.60 (2–5)
Mean age  SD (in years) at diagnosis (range) 65.9  8.8 (41–85)
that have at least two CaP cases; this study is named the
“ProGe`ne” study (Valeri et al. 1996). A total of 924
families have been collected, 293 of which have at least
three affected members. With the same procedure, a set
of 30 well-documented German hereditary-CaP families
was added. Data were processed by use of a laboratory-
developed database for pedigree, clinical, and epidemi-
ological information. From this collection of families, a
set meeting the minimum criteria for genetic analysis
were selected. In brief, and in accordance with the cri-
teria defined by Carter et al. (1992), only families with
at least three confirmed CaP cases, two of whom were
living at the time of the present study, were sampled for
genotyping. The pathological record or the radical-pros-
tatectomy report was the absolute requirement for in-
clusion of families in the final selected set. Prostate-spe-
cific–antigen assays were systematically performed in
every supposedly nonaffected male family member age
140 years, to confirm his nonaffected status. This family
selection allowed 47 families, including 10 families of
German origin, to be studied (table 1).
Genotyping
DNA was prepared from lymphocytes and was used
for PCR. In parallel, collections of serum and immor-
talized lymphoblastoid-cell lines have been set up for
every individual sampled. Microsatellite markers (n 
364) were selected, on the basis of the Ge´ne´thon map
(Dib et al. 1996), to provide an average spacing of 10
cM.
Two successive methods have been used. The first
method, developed at Ge´ne´thon by Vignal et al. (1993),
used a semiautomated microsatellite PCR genotyping.
With this method, 216 markers were analyzed. In brief,
50-ml PCR reactions with 60 ng of DNA/sample were
prepared in 96-well microtiter plates by use of a robotic
dispensing station. This allows a large number to be set
up rapidly and insures accuracy. The products from 16
markers were pooled and coprecipitated before being
loaded on 6% polyacrylamide gels, for separation under
denaturing conditions. After electrophoresis, the ampli-
fied fragments were transferred to Hybond N mem-
branes (Amersham) and then were fixed by UV cross-
linking. PCR, coprecipitation, denaturating PAGE, and
transfer to membranes were performed at Ge´ne´thon
(France). Subsequently, membranes were hybridized
with as many as three nonoverlapping probes and were
stripped and rehybridized as many as 10 times. CEPH
family member 134702 was typed with each marker, to
provide a positive control and size reference (Dib et al.
1996). Allele assignment was made by comparison with
this individual. Membranes were read by at least two
people independently, prior to computer processing.
The second method was accomplished to complete the
marker set (x364 markers) by use of semiautomated
ABI sequencer 377. PCR reactions (total volume 15 ml)
contained 30 ng DNA, 4–50 pmol of each fluorescently
labeled primer, according to individual marker-optimi-
zation parameters, 0.6 U of Taq polymerase, 0.25 mM
each dNTP, 2.5 mM MgCl2, and additional buffer com-
ponents. PCR conditions included initial denaturation
at 95C for 10 min; 10 cycles of denaturation (94C for
15 s), annealing (55C for 15 s), and elongation (72C
for 30 s); 20 cycles of denaturation (89C for 15 s),
annealing (55C for 15 s), and elongation (72C for 30
s); and a final 10-min elongation period at 72C. Three
to five PCR reactions were multiplexed. Twelve aliquots
were pooled into multiplexed nonoverlapping panels
and were analyzed on a semiautomated sequencer. Allele
assignment was performed by use of the Genescan and
Genotyper II package, on the basis of comparison with
CEPH family members 134702 and 88415.
Linkage Analysis
Two-point parametric LOD scores were computed by
use of MLINK from the FASTLINK 3.0P package (La-
throp et al. 1984; Cottingham et al. 1993). Multipoint
parametric LOD scores and nonparametric LOD scores
(Whittemore and Halpern 1994) were computed by use
of GENEHUNTER (Kruglyak et al. 1996). Some con-
trols using LINKMAP (Cottingham et al. 1993) or VI-
TESSE (O’Connell and Weeks 1995) showed no signif-
icant differences in multipoint parametric LOD scores.
We used three genetic models. All models were chosen
on the basis of autosomal dominant inheritance of a gene
whose disease allele has a frequency of .003 and an
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Figure 1 Chromosome 1 scan of 47 families. Maximal two-point LOD scores at a v X .05, computed for models 1 and 2, is plotted
against genetic distance.
overall penetrance of .88 by 85 years of age (Carter et
al. 1992). In these models we used age-dependent pen-
etrance classes, with the following penetrances for the
susceptible genotypes—for example, heterozygote and
eventual homozygote—based on the data in Carter et
al. (1992): .01 at age !40 years, .1 at age 40–55 years,
.5 at age 55–70 years, and .9 at age 170 years. The
difference between these three models was the pene-
trance of the nonsusceptible genotype—for example, the
phenocopy rate—which was .01, in all age classes, for
the first model; 10% of the susceptible-genotype pene-
trance, in all age classes, for the second model; and sim-
ilar to that used by Smith et al. (a constant phenocopy
rate of 15%), in the third model. Women were coded
as unknown. Allelic frequencies were computed on the
basis of 50 independent individuals in our sample. Com-
parison with frequencies published by Dib et al. (1996)
showed no striking differences.
Results and Discussion
To select families displaying a potential hereditary pat-
tern of CaP, we originally referred to the monogenic
autosomal dominant model described by Carter et al.
(1992). In brief, CaP was considered to be hereditary in
families if at least three first-degree relatives were af-
fected or if two relatives had been diagnosed at age !55
years. Although one third of the families identified in
the French ProGe`ne study (Valeri et al. 1996) have at
least three affected members, only a subset (table 1) has
been considered informative for linkage analysis, as a
consequence of (i) missing pathology records, (ii) few
affected members alive and/or available for blood sam-
pling, or (iii) absence of consent. Therefore, a genome-
wide screening has been performed on 47 families, in-
cluding 10 families of German origin. Interestingly, the
mean age at diagnosis of CaP in these 47 families (65.9
years) appeared to be lower than that in a control pop-
ulation of sporadic cases (68.9 years). No associated
pathology, including other cancers, appeared to be sig-
nificantly associated with hereditary CaP.
We analyzed 122 affected and 72 unaffected individ-
uals (table 1) with 364 highly polymorphic microsatellite
markers (including 27 makers on chromosome 1), taken
from the Ge´ne´thon human linkage map (Dib et al. 1996),
which were spaced 10 cM apart. Preliminary evidence
for linkage was obtained with marker D1S2842 (fig. 1
and table 2) on chromosome 1q42.2-43. Two-point link-
age analysis (table 2) and multipoint parametric and
NPL analysis were performed by use of 14 markers span-
ning 40.3 cM of the region of interest, confirming the
localization. We used three different genetic models to
address the problem of the phenocopy rate. Hereditary
CaP represents 5%–10% of all CaP, and the annual age-
adjusted incidence of clinical CaP in the general popu-
lation rises dramatically, from age 40 (1–2/100,000/
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Table 2





LOD SCORE AT v 
.0 .01 .05 .1 .2 .3 .4
1:
D1S2827 9.32 7.42 3.92 2.06 .54 .07 .02
D1S490 3.1 14.03 11.57 6.76 3.93 1.34 .37 .06
D1S2758 2.5 8.56 7.16 4.40 2.75 1.13 .40 .09
D1S2631 3.5 4.47 3.81 2.45 1.58 .65 .22 .05
D1S251 1.4 11.69 9.48 5.18 2.77 .79 .18 .03
D1S2709 2.2 8.70 7.35 4.52 2.71 1.00 .32 .07
D1S446 4.9 9.61 7.72 4.13 2.15 .53 .06 .01
D1S235 2.6 6.36 5.04 2.49 1.05 .03 .20 .09
D1S2678 1.6 3.03 2.50 1.33 .57 .03 .12 .05
D1S2850 0 5.76 4.51 2.24 1.01 .09 .07 .02
D1S2785 9.4 .16 .99 2.34 2.70 2.22 1.27 .42
D1S321 2.3 5.88 4.76 2.50 1.16 .09 .13 .07
D1S2842 5.3 2.04 1.12 .50 1.14 1.18 .72 .25
D1S2811 1.5 9.46 7.40 3.42 1.32 .18 .39 .20
2:
D1S2827 1.06 .96 .65 .39 .11 .01 .01
D1S490 3.1 3.09 2.87 2.14 1.47 .63 .22 .05
D1S2758 2.5 2.18 2.07 1.66 1.25 .65 .27 .07
D1S2631 3.5 1.37 1.29 1.03 .76 .38 .16 .04
D1S251 1.4 1.90 .75 1.26 .83 .34 .12 .03
D1S2709 2.2 1.85 1.73 1.30 .89 .40 .15 .04
D1S446 4.9 1.24 1.14 .80 .50 .16 .04 .00
D1S235 2.6 .51 .44 .21 .03 .09 .08 .03
D1S2678 1.6 .19 .14 .02 .08 .12 .08 .02
D1S2850 0 1.12 1.02 .70 .43 .14 .04 .01
D1S2785 9.4 2.10 2.08 1.95 1.73 1.17 .61 .19
D1S321 2.3 .90 .80 .49 .24 .01 .05 .02
D1S2842 5.3 .75 .76 .77 .73 .54 .30 .10
D1S2811 1.5 1.04 .91 .49 .16 .13 .16 .08
a Between the marker immediately to the left and that directly above it.
year) to a peak during the 80s (1,600/100,000/year),
which gives an estimated overall lifetime risk of 10%
(Boyle et al. 1996). Since it is impossible to estimate the
phenocopy rate in our population of families with mul-
tiple cases, we have designed three different models.
Model 1 considers a low, constant phenocopy rate of
1%. Because hereditary cases are often associated with
an early age at onset (see discussion above), it seems
reasonable to use a further model (model 2), which has
a phenocopy number that increases with age. We used
age-dependent penetrance classes to extract information
for unaffected men. A third model, close to the model
used by Smith et al. (1996), yielded similar profiles, with
magnitude lower than that in our models 1 and 2 (two-
point LOD score of 1.33 at a recombination fraction (v)
of 0, multipoint LOD score of 1.55 for maker D1S2785).
Our data show a two-point LOD score of 2.7 at v 
.1 (model 1), with D1S2785 (table 2). A multipoint LOD
score of 1.89 is obtained under model 2 (fig. 2), and,
under the hypothesis of heterogeneity, model 1 gives an
HLOD score of 2.2 (fig. 2). The NPL-all statistic (Whit-
temore and Halpern 1994), which is independent of the
genetic model, confirms these findings, reaching 3.1,
with P  .001 (fig. 2). The value of a, proportion of
families with linkage to this locus, was determined in
two ways. GENEHUNTER was used to compute HLOD
(Smith 1963), which is a parametric LOD score maxi-
mized on a (Kruglyak et al. 1996). Under model 1, a 
48%. Model 2 does not show heterogeneity near the
maximum LOD score. A homogeneity analysis, using
the program HOMOG (Morton 1956; Ott 1986) with
multipoint LOD scores, gave a similar a (50%), with a
of 157/1 likelihood ratio in favor of heterogeneity, for
model 1. Model 2 showed no clear evidence in favor of
heterogeneity. However, the lower limit of the condi-
tional probability of linkage showed that families could
be divided into two groups. Furthermore, information
on heterogeneity, in both our current linkage analysis
and that of others (Smith et al. 1996), suggests that
several genes may account for all cases of inherited CaP.
In nine families, the age at diagnosis of all affected
members in the last generation was !60 years (range
48–60 years). We analyzed this subset of families for
heterogeneity of the recombination frequency, by com-
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Figure 2 Multipoint LOD scores and NPL scores for 47 families, computed with GENEHUNTER, on a map of four markers. HLODs
are maximized on a.
Table 3







LOD SCORE AT v 
.0 .01 .05 .1 .2 .3 .4
1:
D1S235 .36 .36 .33 .29 .20 .10 .03
D1S2678 1.6 .73 .57 .25 .08 .04 .05 .02
D1S2785 9.4 2.06 2.15 2.17 1.97 1.39 .77 .27
D1S2842 7.6 .93 .43 .40 .71 .71 .45 .17
2:
D1S235 .51 .44 .21 .03 .09 .08 .03
D1S2678 1.6 .24 .24 .21 .18 .12 .06 .02
D1S2785 9.4 1.75 1.70 1.51 1.27 .81 .42 .14
D1S2842 7.6 .66 .67 .66 .61 .44 .25 .09
a As defined in the footnote to table 2.
parison with the other families. For this analysis, we used
the predivided sample test (Morton 1956) with the Mtest
program and multipoint, instead of two-point, LOD
scores. A highly significant x2 (1 df) of 16.25 (P ! .0001)
is obtained with model 1. Two-point (table 3) and mul-
tipoint LOD scores and NPL scores were computed for
this subset of families. An identical value of 3.3 for mul-
tipoint LOD and NPL scores was reached, at marker
D1S2785, by model 1 (fig. 3). Haplotypes reconstructed
with GENEHUNTER showed, in each of these nine fam-
ilies, one haplotype segregating in all affected individ-
uals. However, no critical recombinant allowing a nar-
rowing of the candidate region was characterized. These
data are suggestive of familial clustering with the age at
diagnosis, since we have observed in our populations
(Valeri et al. 1996) an earlier age at diagnosis is corre-
lated with an increase in the number of CaP cases ob-
served per family: 68.5 years for one CaP case/family,
67.0 years for two CaP cases/family, 65.6 years for three
CaP cases/family, and 60.6 for four or more CaP cases/
family (in both 579 families with sporadic cases and 924
families with two or more cases).
Although the two-point LOD scores do not reach the
critical threshold value of 3, these data are obtained with
multiple LOD scores (model 1). Furthermore, a LOD
score of 3.3 is reached with early-onset families (para-
metric and nonparametric scores). The two-point and
multipoint LOD-score results obtained do not rule out
the possibility of false-positive values. Ge´nin et al. (1995)
showed that, for a certain family structure and for a
dominant disease, the posterior probability of no link-
age, with a two-point LOD score of 3.0, is 8%–16%.
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Figure 3 Multipoint LOD scores and NPL scores for nine families with early-onset familial CaP, computed with GENEHUNTER, on a
map of four markers.
However, this result is strongly dependent on the family
structure and the genetic model. A first cause of errors
could be a misspecification of genetic parameters at the
disease locus. However, Clerget-Darpoux et al. (1986)
showed that this leads more likely to false-negative er-
rors. Another well-known cause of false-positive results
is the use of wrong allelic frequencies at marker loci
(Freimer et al. 1993). Since we have used allelic fre-
quencies derived from the population under study, which
correlate well with published values, we can rule out this
cause of errors. We have also addressed this problem by
running simulations at v  .5 and a  0, for two- and
three-point LOD scores, thus modeling no linkage. De-
spite the fact that run-time limitations did not allow us
to analyze enough replicas to achieve full statistical sig-
nificance, the data in the present study show that the
probability of false-positive results above a LOD-score
value of 3.0 is !5%–10%.
With regard to heterogeneity, the 50% estimate found
by homogeneity analysis is probably an overestimation
partly due to the number of families with only two fully
informative meioses. A lower limit for a (∼20%) is de-
rived from the 9/47 ratio of families with early-onset
CaP cases to the total number of families with CaP cases.
A better estimation of a would require a metanalysis of
a worldwide collection of families. Taken together, these
results allow us to propose that PCaP is localized on
chromosome 1q42.2-43 and accounts for X50% cases
of hereditary CaP.
Smith et al. (1996) have described a locus on chro-
mosome 1q24-25 that has evidence of linkage, after an
analysis of a set of North American and Swedish fam-
ilies. This locus maps 60 cM centromeric to the region
on 1q42.2-43, described in the present report. A linkage
analysis was performed on the 1q24-25 locus, and, in
agreement with the data recently published by others
(Cannon-Albright and Neuhausen 1997; Eeles et al.
1997; McIndoe et al. 1997; Thibodeau et al. 1997), we
found no evidence of linkage within this region (table
4). Several reasons for discrepancy between our data and
the data of Smith et al. (1996) could include the differ-
ences in the number of families (47 vs. 91), in the mean
number of affected individuals (3.3/family vs. 4.9/fam-
ily), and in the mean number of genotyped individuals
(4.1/family vs. 6.6/family). The differences in the ethnic
composition of the samples also could be responsible for
different results. Since both populations have similar but
also different origins, it seems very difficult to further
analyze that matter. Also interesting is the fact that, in
the chromosome 1 scan by Smith et al. (1996, fig. 1),
they observed a hit at marker D1S235. This marker is
centromeric (table 2) to the locus that we have studied
and in effect may have presaged our findings.
We have recently examined the 1q24-25 region for
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Table 4





LOD SCORE AT v 
.0 .01 .05 .1 .2 .3 .4
1:
D1S218 13.05 10.41 5.59 3.02 .88 .16 .03
D1S238 11.9 13.12 10.48 5.62 3.02 .89 .19 .01
D1S413 7.6 10.4 8.55 4.86 2.75 .91 .24 .03
2:
D1S218 2.07 1.93 1.47 1.01 .42 .13 .01
D1S238 11.9 2.11 1.95 1.42 .95 .39 .14 .02
D1S413 7.6 1.89 1.76 1.30 .89 .39 .14 .03
a As defined in the footnote to table 2.
loss of heterozygosity (LOH) in sporadic prostate tu-
mors, and LOH has been found in 9/55 tumors (Latil
et al. 1997). We have further supplemented this previous
study, with microsatellite markers, to analyze the
1q42.2-43 region in sporadic tumors. In five of the nine
1q24-25–deleted tumors, the deletion overlapped with
the distal 1q42.2-43 region. Furthermore, allelic loss at
1q42.2-43 was seen in six tumors without any alteration
within the 1q24-25 region. Taken together, these results
suggest that chromosome 1q could harbor two genes
involved during progression of CaP.
A small number of genes of interest are known to map
to the candidate locus; they include PCTA-1, a member
of the galectin family (Su et al. 1996); the poly (ADP-
ribose) polymerase (Lyn et al. 1993); and the RAS-re-
lated GTP-binding protein RAB-4 (Rousseau-Merck et
al. 1991). Also, a fragile site (Feichtinger and Schmid
1989) and replication-error–type genetic instability have
been observed within the 1q42-43 region (Murty et al.
1994); the last reveals a potential association with he-
reditary nonpolyposis colorectal cancer. Also, this region
has been shown to be involved in translocations in glio-
blastomas (Li et al. 1995).
Although screening in the general population is still
under debate in Western countries, evidence of familial
inheritance should be the basis for genetic screening of
this population at risk (Narod et al. 1995). As a matter
of fact, the relative risk could rise to 11 when three first-
degree relatives are affected (Steinberg et al. 1990;
McWorther et al. 1992; Tulinius et al. 1992; Sellers et
al. 1994; Aprikian et al. 1995; Monroe et al. 1995; Whit-
temore et al. 1995; Lesko et al. 1996). Therefore, the
development of reliable tests could greatly help clinicians
in genetic counseling.
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